RT Journal Article SR Electronic T1 Circular RNA detection identifies circPSEN1 alterations in brain specific to Autosomal Dominant Alzheimer Disease JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.10.29.21265617 DO 10.1101/2021.10.29.21265617 A1 Chen, Hsiang-Han A1 Eteleeb, Abdallah A1 Wang, Ciyang A1 Fernandez, Maria Victoria A1 Budde, John P. A1 Bergmann, Kristy A1 Norton, Joanne A1 Wang, Fengxian A1 Ebl, Curtis A1 Morris, John C. A1 Perrin, Richard J. A1 Bateman, Randall J. A1 McDade, Eric A1 Xiong, Chengjie A1 Goate, Alison A1 Farlow, Martin A1 Chhatwal, Jasmeer A1 Schofield, Peter R A1 Chui, Helena A1 Harari, Oscar A1 Cruchaga, Carlos A1 Ibanez, Laura A1 Dominantly Inherited Alzheimer Network YR 2021 UL http://medrxiv.org/content/early/2021/10/30/2021.10.29.21265617.abstract AB Background Autosomal-dominant Alzheimer’s disease (ADAD) is caused by pathogenic mutations in APP, PSEN1, and PSEN2, which usually lead to an early age at onset (<65). Circular RNAs are a family of non-coding RNAs highly expressed in the nervous system and especially in synapses. We aimed to investigate differences in brain gene expression of linear and circular transcripts from the three ADAD genes in controls, sporadic AD, and ADAD.Methods We obtained and sequenced RNA from brain cortex using standard protocols. Linear counts were obtained using the TOPMed pipeline; circular counts, using python package DCC. After stringent quality control (QC), we obtained the counts for PSEN1, PSEN2 and APP genes. Only circPSEN1 passed QC. We used DESeq2 to compare the counts across groups, correcting for biological and technical variables. Finally, we performed in-silico functional analyses using the Circular RNA interactome website and DIANA mirPath software.Results Our results show significant differences in gene counts of circPSEN1 in ADAD individuals, when compared to sporadic AD and controls (ADAD=22, AD=274, Controls=25 – ADADvsCO: log2FC=0.786, p=9.08×10-05, ADADvsAD: log2FC=0.576, p=2.00×10-03). The high gene counts are contributed by two circPSEN1 species (hsa_circ_0008521 and hsa_circ_0003848). No significant differences were observed in linear PSEN1 gene expression between cases and controls, indicating that this finding is specific to the circular forms. In addition, the high circPSEN1 levels do not seem to be specific to PSEN1 mutation carriers; the counts are also elevated in APP and PSEN2 mutation carriers. In-silico functional analyses suggest that circPSEN1 is involved in several pathways such as axon guidance (p=3.39×10−07), hippo signaling pathway (p=7.38×10−07), lysine degradation (p=2.48×10−05) or Wnt signaling pathway (p=5.58×10−04) among other KEGG pathways. Additionally, circPSEN1 counts were able to discriminate ADAD from sporadic AD and controls with an AUC above 0.70.Conclusions Our findings show the differential expression of circPSEN1 is increased in ADAD. Given the biological function previously ascribed to circular RNAs and the results of our in-silico analyses, we hypothesize that this finding might be related to neuroinflammatory events that lead or that are caused by the accumulation of amyloid-beta.Competing Interest StatementThe funders of the study had no role in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. CC is a member of the advisory board of Vivid genetics, Halia Therapeutics and ADx Healthcare and has received research support from Biogen, EISAI, Alector and Parabon. The rest of the authors report no conflict of interest.Funding StatementThis work was supported by grants from the National Institutes of Health (K99-AG062723 (LI), R01AG044546 (CC), P01AG003991, RF1AG053303 (CC), R01AG058501 (CC), U01AG058922 (CC), K01AG046374, and R01HL119813), the Alzheimer Drug Discovery Foundation (GDAPB-201807-2015632), Bright Focus Foundation (A2021033S) and Department of Defense (W81XWH2010849). The recruitment and clinical characterization of participants who enrolled in the Knight-ADRC was supported by NIH P30 AG066444 Data collection and sharing for this project was supported by The Dominantly Inherited Alzheimer Network (DIAN, U19AG032438) funded by the National Institute on Aging (NIA), the Alzheimer Association (SG-20-690363-DIAN), the German Center for Neurodegenerative Diseases (DZNE), Raul Carrea Institute for Neurological Research (FLENI), Partial support by the Research and Development Grants for Dementia from Japan Agency for Medical Research and Development, AMED, and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), Spanish Institute of Health Carlos III (ISCIII), Canadian Institutes of Health Research (CIHR), Canadian Consortium of Neurodegeneration and Aging, Brain Canada Foundation, and Fonds de Recherche du Quebec - Sante.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Boards of Washington University School of Medicine in St. Louis approved the study, and research was carried out in accordance with the approved protocols. Written informed consent was obtained from all participants or their family members.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDiscovery dataset data corresponding to the participants who enrolled in the Knight-ADRC can be downloaded at the NIAGADS Knight ADRC collection (NG00083). Additional Knight-ADRC participants and DIAN data is available upon request to qualified researchers. Finally, MSBB dataset is publicly available in Synapse (syn3159438).